注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Cabaletta Bio Inc是一家臨床階段生物技術公司。該公司專注於發現和開發針對B細胞介導的自身免疫疾病的工程化T細胞療法。T細胞被設計為選擇性結合和清除產生致病性自身抗體的B細胞,或致病性B細胞,同時保留正常B細胞。該公司的候選產品包括DSG3-CAART、DSG3/1-CAART、MuSK-CAART、PLA2R-CAART和FVIII-CAART。DSG3-CAART用於治療粘膜尋常型天皰瘡(mPV),這是一種影響粘膜上皮的尋常型天皰瘡(PV)亞型。DSG3/1-CAART專為粘膜皮膚尋常性天皰瘡(mcPV)設計。MuSK-CAART用於治療肌肉特異性激酶(MuSK)和重症肌無力(MG)。PLA2R-CAART用於治療磷脂酶A2受體(PLA2R)相關的膜性腎病。FVIII-CAART,設計用於治療a型血友病患者群體。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Jay Philip Siegel | 68 | - | Member of Scientific Advisory Board |
Michael C. Milone | - | - | Co-Founder & Co-Chair of Scientific Advisory Board |
Mark J. Simon | 59 | 2018 | Independent Director |
Aimee Payne | - | - | Co-Founder & Co-Chair of Scientific Advisory Board |
Steven A. Nichtberger | 60 | 2017 | Co-Founder, Chairman, CEO & President |
Brian F. Daniels | 62 | 2018 | Member of Scientific Advisory Board |
Drew Weissman | - | 2021 | Member of Scientific Advisory Board |
Georg A. Schett | - | 2022 | Member of Scientific Advisory Board |
Scott C. Brun | 55 | 2021 | Independent Director |
Catherine Bollard | 55 | 2019 | Independent Director |
Iain B. McInnes | 58 | 2020 | Member of Scientific Advisory Board |
Carl H. June | 69 | 2020 | Member of Scientific Advisory Board |
Shawn Cline Tomasello | 64 | 2023 | Independent Director |
Richard C. Henriques | 68 | 2019 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核